Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$244.28 USD

244.28
1,118,394

+1.81 (0.75%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for RMD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for ResMed Inc falls in the month of June.

All items in Millions except Per Share data.

6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020
Assets          
Cash & Equivalents 238 228 274 295 463
Receivables 837 705 576 614 475
Notes Receivable 0 0 0 0 0
Inventories 822 998 744 457 417
Other Current Assets 460 437 338 208 169
Total Current Assets 2,358 2,368 1,931 1,575 1,523
Net Property & Equipment 548 538 498 463 417
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 204 133 80 80 41
Intangibles 3,328 3,323 2,282 2,320 2,338
Deposits & Other Assets 284 262 172 161 149
Total Assets 6,872 6,752 5,096 4,728 4,587
Liabilities & Shareholders Equity 6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020
Notes Payable 10 10 10 12 12
Accounts Payable 238 151 159 138 136
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 378 366 345 321 270
Income Taxes Payable 108 72 45 308 65
Other Current Liabilities 153 138 109 110 99
Total Current Liabilities 911 759 689 912 603
Mortgages 0 0 0 0 0
Deferred Taxes/Income 217 210 105 103 100
Convertible Debt 0 0 0 0 0
Long-Term Debt 697 1,431 765 643 1,164
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 42 105 55 70 121
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,008 2,622 1,735 1,842 2,090
Shareholders Equity 6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 1,897 1,772 1,682 1,622 1,571
Retained Earnings 4,992 4,253 3,614 3,080 2,833
Other Equity -252 -273 -313 -193 -284
Treasury Stock 1,773 1,623 1,623 1,623 1,623
Total Shareholder's Equity 4,864 4,130 3,361 2,886 2,497
Total Liabilities & Shareholder's Equity 6,872 6,752 5,096 4,728 4,587
Total Common Equity 4,864 4,130 3,361 2,886 2,497
Shares Outstanding 146.91 146.93 146.20 145.50 144.60
Book Value Per Share 33.11 28.11 22.99 19.83 17.27

Fiscal Year End for ResMed Inc falls in the month of June.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents -99,573 238 238 210 209
Receivables 811 837 779 730 692
Notes Receivable NA 0 0 0 0
Inventories 918 822 829 933 958
Other Current Assets 486 460 505 505 445
Total Current Assets 2,641 2,358 2,351 2,378 2,305
Net Property & Equipment 560 548 540 552 534
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges 221 204 162 156 138
Intangibles 3,365 3,328 3,337 3,390 3,375
Deposits & Other Assets 279 284 277 276 265
Total Assets 7,222 6,872 6,815 6,905 6,741
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable 10 10 10 10 10
Accounts Payable 249 238 177 202 177
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses 366 378 356 332 348
Income Taxes Payable 94 108 55 47 67
Other Current Liabilities 157 153 151 149 147
Total Current Liabilities 904 911 773 764 771
Mortgages NA 0 0 0 0
Deferred Taxes/Income 228 217 219 217 209
Convertible Debt NA 0 0 0 0
Long-Term Debt 668 697 997 1,217 1,352
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities 83 60 85 46
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities 2,027 2,008 2,185 2,423 2,490
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 1,925 1,897 1,848 1,823 1,791
Retained Earnings 5,225 4,992 4,770 4,540 4,402
Other Equity -132 -252 -265 -208 -320
Treasury Stock 1,823 1,773 1,723 1,673 1,623
Total Shareholder's Equity 5,195 4,864 4,630 4,482 4,250
Total Liabilities & Shareholder's Equity 7,222 6,872 6,815 6,905 6,741
Total Common Equity 105,194 4,864 4,630 4,482 4,250
Shares Outstanding 146.77 146.91 146.90 147.00 147.00
Book Value Per Share 716.73 33.11 31.52 30.49 28.91